New facility brings the most advanced cellular therapies to patients
Stem cell transplants spread their availability and enhance outcomes for patients, both young and old with constant progress. This past year, University of Chicago Medicine built a new, state-of-the-art facility to handle and create cells for therapeutic purposes, rather than reconstructing their 17-year-old stem cell transplant facility.
Indeed, the new Advanced Cellular Therapeutics Facility (ACTF) increases their capabilities for existing therapies, as well as creating new types of products for treating various medical conditions. What is more, the new facility contributes to the hospital’s hematopoietic stem cell transplantation program. It achieves this goal by generating and preparing all blood-based cells for stem cell/bone marrow transplantation for adult as well as pediatric patients.
In addition, the new facility will have the capabilities for manufacturing novel cell therapies such as CAR T-cells , which have shown great promise for the treatment of leukemia and lymphoma.
Furthermore, the new 10,000-square-feet facility provides good tissue practice (GTP) guidelines and clean rooms compatible with current good manufacturing (cGMP) guidelines.
Beyond the previous operation, these clinical manufacturing spaces, the facility includes quality testing, as well as generating and scaling up new cellular therapies from investigator-initiated and pharmaceutical company-sponsored clinical trials.
In fact, the ACTF is registered with the U.S. Food and Drug Administration. At the moment, the hematopoietic stem cell transplantation program completes more than 200 adult and pediatric stem cell transplants a year. Moreover, they conduct a large number of clinical trials and commercial cell therapy contracts with pharmaceutical/biotechnology companies.